Document:

Exhibit 4.14

ELEVENTH SUPPLEMENTAL INDENTURE

          SUPPLEMENTAL
INDENTURE dated as of June 22, 2007 (this “Eleventh Supplemental Indenture”),
among AMERIPATH OHIO, INC., TID ACQUISITION CORP. and AMERIPATH, INC., each a
Delaware corporation, DERMATOPATHOLOGY SERVICES, INC. and SHOALS PATHOLOGY
ASSOCIATES, INC., each an Alabama corporation, AMERIPATH CONSOLIDATED LABS,
INC. and AMERIPATH MARKETING USA, INC., each a Florida corporation, AMERIPATH
KENTUCKY, INC., a Kentucky corporation, AMERIPATH MICHIGAN, INC., a Michigan
corporation, PCA OF DENVER, INC. and PCA OF NASHVILLE, INC., each a Tennessee
corporation, AMERIPATH MISSISSIPPI, INC., a Mississippi corporation, AMERIPATH
NORTH CAROLINA, INC., a North Carolina corporation, AMERIPATH PHILADELPHIA, INC.,
a New Jersey corporation, ANATOMIC PATHOLOGY SERVICES, INC., an Oklahoma
corporation, ARIZONA PATHOLOGY GROUP, INC., an Arizona corporation, AMERIPATH
SC, INC., a South Carolina corporation, AMERIPATH YOUNGSTOWN LABS, INC., an
Ohio corporation, OCMULGEE MEDICAL PATHOLOGY ASSOCIATION, INC., KAILASH B.
SHARMA, M.D., INC., SHARON G. DASPIT, M.D., INC. and PETER G. KLACSMANN, M.D.,
INC., each a Georgia corporation, HEMOCUE, INC. and SPECIALTY LABORATORIES,
INC., each a California corporation, STRIGEN, INC., a Utah corporation,
AMERIPATH FLORIDA, LLC, AMERIPATH HOSPITAL SERVICES FLORIDA, LLC, AMERIPATH NEW
YORK, LLC, API NO. 2, LLC and AMERIPATH, LLC, each a Delaware limited liability
company, DIAGNOSTIC PATHOLOGY MANAGEMENT SERVICES, INC., an Oklahoma limited liability
company, AMERIPATH INDIANA, LLC, an Indiana limited liability company, REGIONAL
PATHOLOGY CONSULTANTS, LLC and ROCKY MOUNTAIN PATHOLOGY, LLC, each a Utah
limited liability company, O’QUINN MEDICAL PATHOLOGY ASSOCIATION, LLC, a
Georgia limited liability company, AMERIPATH PENNSYLVANIA, LLC, a Pennsylvania
limited liability company, AMERIPATH TEXAS, L.P., a Texas limited partnership
and AMERIPATH WISCONSIN, LLC, a Wisconsin limited liability company (the
“Additional Subsidiary Guarantors”), QUEST DIAGNOSTICS INCORPORATED, a Delaware
corporation (the “Company”), and THE BANK OF NEW YORK, a New York banking
corporation, as Trustee (the “Trustee”).

RECITALS OF THE COMPANY

                    WHEREAS,
the Company, the Trustee and the Initial Subsidiary Guarantors (as hereinafter
defined) executed and delivered an Indenture, dated as of June 27, 2001
(the “Base Indenture”), as supplemented by the first supplemental indenture,
dated as of June 27, 2001, among the Company, the Initial Subsidiary Guarantors
(as defined therein) party thereto, and the Trustee, as further supplemented by
a second supplemental indenture, dated as of November 26, 2001, among the
Company, the Subsidiary Guarantors (as defined therein) party thereto and the
Trustee, as further supplemented by a third supplemental indenture, dated as of
April 4, 2002, among the Company, the additional Subsidiary Guarantors (as
defined therein) party thereto and the Trustee, as further supplemented by a
fourth supplemental indenture, dated as of March 19, 2003, among the Company,
the additional Subsidiary Guarantors (as defined therein) party thereto and the
Trustee, as further supplemented by a fifth supplemental indenture, dated as of

1

April 16, 2004, among the
Company, the additional Subsidiary Guarantors (as defined therein) party
thereto and the Trustee, as further supplemented by a sixth supplemental
indenture dated October 31, 2005, among the Company, the Subsidiary Guarantors
(as defined therein) party thereto, as further supplemented by a seventh supplemental
indenture dated November 21, 2005, among the Company, the additional Subsidiary
Guarantors (as defined therein) parties thereto and the Trustee, as further
supplemented by an eighth supplemental indenture dated July 31, 2006, among the
Company, the additional Subsidiary Guarantors (as defined therein) parties
thereto and the Trustee, as further supplemented by a ninth supplemental
indenture, dated as of September 30, 2006, among the Company the additional
Subsidiary Guarantors (as defined therein) party thereto and the Trustee, as
further supplemented by a tenth supplemental indenture, dated as of June 22,
2007, among the Company and the Trustee, to be further supplemented by this
Eleventh Supplemental Indenture (collectively, the “Indenture”), to provide for
the issuance by the Company from time to time of Securities to be issued in one
or mores series as provided in the Indenture;

                    WHEREAS,
the Additional Subsidiary Guarantors intend to guarantee the Securities under
the Indenture and the issuance of guarantees has been authorized by resolutions
adopted by the Boards of Directors of such Additional Subsidiary Guarantors; 

                    WHEREAS,
Sections 901(1) and 901(11) of the Indenture provide that without the consent
of Holders of the Securities of any series issued under the Indenture, the
Company and the Subsidiary Guarantors, when authorized by a Board Resolution,
and the Trustee may enter into one or more indentures supplemental to the
Indenture to (a) evidence the successor of another Person to any Subsidiary
Guarantor and the assumption by such successor of the covenants of such
Subsidiary Guarantor in the Indenture and in the Securities and (b) add a
guarantor or guarantors for any series or all series of the Securities;

                    WHEREAS,
pursuant to Sections 904, 1601, 1602 and 1604 of the Indenture, by delivery of
a Supplemental Indenture to the Trustee in accordance with the terms of the
Indenture, each Person that becomes a Subsidiary Guarantor after the date of
the Base Indenture will be deemed to have executed and delivered the Subsidiary
Guarantee for the benefit of the Holder of the Security upon which the
Subsidiary Guarantee is endorsed, with the same effect as if such Subsidiary
Guarantor had been named thereon and had executed and delivered the Subsidiary
Guarantee; and

                    WHEREAS,
all things necessary to make this Eleventh Supplemental Indenture a valid
supplement to the Indenture according to its terms and the terms of the
Indenture have been done;

                    NOW,
THEREFORE, for and in consideration of the foregoing, the parties hereto hereby
enter into this Eleventh Supplemental Indenture, for the equal and
proportionate benefit of all Holders of the Securities, as follows:

                    SECTION
1 Certain Terms Defined in the Indenture.

2

                    All
capitalized terms used but not defined herein shall have the meanings assigned
to them in the Indenture.

                    SECTION
2 Agreement to Guarantee.

                    The
Additional Subsidiary Guarantors, by their signature below, agree to become
Additional Subsidiary Guarantors under the Indenture with the same force and
effect as if originally named therein as Subsidiary Guarantors. The Additional
Subsidiary Guarantors hereby agree to all the terms and provisions of the
Indenture applicable to them as Additional Subsidiary Guarantors thereunder and
each reference to a “Subsidiary Guarantor” in the Indenture shall be deemed to
include the Additional Subsidiary Guarantors.

                    SECTION
3 Indenture remains in Full Force and Effect.

                    Except
as expressly supplemented by this Eleventh Supplemental Indenture, the
Indenture shall remain in full force and effect in accordance with its terms.

                    SECTION
4 New York Law to Govern.

                    THIS
ELEVENTH SUPPLEMENTAL INDENTURE SHALL BE GOVERNED BY AND CONSTRUED IN
ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO PRINCIPLES
OF CONFLICT OF LAWS.

                    SECTION
5 Separability.

                    In
case any one or more of the provisions contained in this Eleventh Supplemental
Indenture should be held invalid, illegal or unenforceable in any respect, the
validity, legality and enforceability of the remaining provisions contained
herein and in the Indenture shall not in any way be affected or impaired. The
parties hereto shall endeavor in good faith negotiations to replace any
invalid, illegal or enforceable provisions herein with valid provisions, the
economic effect of which comes as close as possible to that of the invalid,
illegal or unenforceable provisions.

                    SECTION
6 May be Executed in Counterparts.

                    This
Eleventh Supplemental Indenture may be executed in counterparts, each of which
when taken together shall constitute one and the same instrument. This Eleventh
Supplemental Indenture shall become effective when the Trustee shall have
received a counterpart thereof that bears the signatures of the Additional
Subsidiary Guarantors.

                    SECTION
7 Trustee.

                    The
Trustee makes no representations as to the validity or sufficiency of this
Eleventh Supplemental Indenture. The recitals and statements herein are deemed
to be those of the Company and the Additional Subsidiary Guarantors and not of
the Trustee. 

3

                    IN
WITNESS WHEREOF, the Company, the Additional Subsidiary Guarantors, and the
Trustee have duly executed this Eleventh Supplemental Indenture as of the day
and year first above written.

	
 

	
 

	
 

	
 

	
QUEST DIAGNOSTICS INCORPORATED

	
 

	
 

	
 

	
By: 

	
 /s/ Robert A. Hagemann 

	
 

	
 

	

	
 

	
 

	
 

	
Name: Robert A. Hagemann 

	
 

	
Title:
  Senior Vice President and Chief Financial Officer 

	
 

	
 

	
 

	
AMERIPATH,
  INC.

	
 

	
AMERIPATH
  CONSOLIDATED LABS, INC.

	
 

	
AMERIPATH
  FLORIDA, LLC

	
 

	
AMERIPATH
  HOSPITAL SERVICES FLORIDA, LLC

	
 

	
AMERIPATH
  INDIANA, LLC

	
 

	
AMERIPATH
  KENTUCKY, INC.

	
 

	
AMERIPATH
  MARKETING USA, INC.

	
 

	
AMERIPATH
  MICHIGAN, INC.

	
 

	
AMERIPATH
  MISSISSIPPI, INC.

	
 

	
AMERIPATH
  NEW YORK, LLC

	
 

	
AMERIPATH
  NORTH CAROLINA, INC.

	
 

	
AMERIPATH
  OHIO, INC.

	
 

	
AMERIPATH
  PENNSYLVANIA, LLC

	
 

	
AMERIPATH
  PHILADELPHIA, INC.

	
 

	
AMERIPATH
  SC, INC.

	
 

	
AMERIPATH
  YOUNGSTOWN LABS, INC.

	
 

	
AMERIPATH
  WISCONSIN, LLC

	
 

	
AMERIPATH,
  LLC

	
 

	
API
  NO.2, LLC

	
 

	
ANATOMIC
  PATHOLOGY SERVICES, INC.

	
 

	
ARIZONA
  PATHOLOGY GROUP, INC.

	
 

	
DERMATOPATHOLOGY
  SERVICES, INC.

	
 

	
DIAGNOSTIC
  PATHOLOGY MANAGEMENT SERVICES, LLC

	
 

	
KAILASH
  B. SHARMA, M.D., INC.

4

	
 

	
 

	
 

	
 

	
OCMULGEE
  MEDICAL PATHOLOGY ASSOCIATION INC.

	
 

	
O’QUINN
  MEDICAL PATHOLOGY ASSOCIATION, LLC

	
 

	
PCA
  OF DENVER, INC.

	
 

	
PCA
  OF NASHVILLE, INC.

	
 

	
PETER
  G. KLACSMANN M.D., INC.

	
 

	
REGIONAL
  PATHOLOGY CONSULTANTS, LLC

	
 

	
ROCKY
  MOUNTAIN PATHOLOGY, LLC

	
 

	
SHARON
  G. DASPIT, M.D., INC.

	
 

	
SHOALS
  PATHOLOGY ASSOCIATES, INC.

	
 

	
SPECIALTY
  LABORATORIES, INC.

	
 

	
STRIGEN,
  INC.

	
 

	
TID
  ACQUISITION CORP.

	
 

	
 

	
 

	
By:

	
 /s/ Robert
    A. Hagemann 

	
 

	
 

	

	
 

	
  Name:
  Robert A. Hagemann 

	
 

	
  Title:
  Vice President

	
 

	
 

	
 

	
AMERIPATH
  TEXAS, L.P.

	
 

	
 

	
 

	
By:
  AmeriPath LLC

	
 

	
 

	
 

	
By:

	
 /s/ Robert
    A. Hagemann 

	
 

	
 

	

	
 

	
  Name:
  Robert
    A. Hagemann

	
 

	
  Title:
  Vice President

	
 

	
 

	
 

	
HEMOCUE,
  INC.

	
 

	
 

	
 

	
By:

	
 /s/ Robert
    A. Hagemann 

	
 

	
 

	

	
 

	
  Name:
  Robert A. Hagemann 

	
 

	
  Title:
  Vice President

5

	
 

	
 

	
 

	
 

	
THE
  BANK OF NEW YORK

	
 

	
 

	
 

	
By:

	
 /s/ Robert
    A. Massimillo

	
 

	
 

	

	
 

	
 

	
Name: Robert
    A. Massimillo

	
 

	
Title: Vice
    President 

6ex4-15_.htm -- Converted by SEC Publisher, created by BCL Technologies Inc., for SEC Filing

Exhibit 4.15 

TWELFTH SUPPLEMENTAL INDENTURE 

     SUPPLEMENTAL INDENTURE dated as of June 25, 2007 (this “Twelfth Supplemental Indenture”), among AMERIPATH GROUP HOLDINGS, INC., AMERIPATH HOLDINGS, INC., AMERIPATH INTERMEDIATE HOLDINGS, INC. (the “Additional
AmeriPath Subsidiaries”) and MEDPLUS, INC. (“MedPlus”) each a Delaware corporation (the Additional AmeriPath Subsidiaries, together with MedPlus, the “Additional Subsidiary Guarantors”), QUEST DIAGNOSTICS INCORPORATED, a
Delaware corporation (the “Company”), and THE BANK OF NEW YORK, a New York banking corporation, as Trustee (the “Trustee”). 

RECITALS OF THE COMPANY 

     WHEREAS, the Company, the Trustee and the Initial Subsidiary Guarantors (as hereinafter defined) executed and delivered an Indenture, dated as of June 27, 2001 (the “Base Indenture”), as
supplemented by the first supplemental indenture, dated as of June 27, 2001, among the Company, the Initial Subsidiary Guarantors (as defined therein) party thereto, and the Trustee, as further supplemented by a second supplemental indenture, dated
as of November 26, 2001, among the Company, the Subsidiary Guarantors (as defined therein) party thereto and the Trustee, as further supplemented by a third supplemental indenture, dated as of April 4, 2002, among the Company, the additional
Subsidiary Guarantors (as defined therein) party thereto and the Trustee, as further supplemented by a fourth supplemental indenture, dated as of March 19, 2003, among the Company, the additional Subsidiary Guarantors (as defined therein) party
thereto and the Trustee, as further supplemented by a fifth supplemental indenture, dated as of April 16, 2004, among the Company, the additional Subsidiary Guarantors (as defined therein) party thereto and the Trustee, as further supplemented by a
sixth supplemental indenture dated October 31, 2005, among the Company, the Subsidiary Guarantors (as defined therein) party thereto, as further supplemented by a seventh supplemental indenture dated November 21, 2005, among the Company, the
additional Subsidiary Guarantors (as defined therein) parties thereto and the Trustee, as further supplemented by an eighth supplemental indenture dated July 31, 2006, among the Company, the additional Subsidiary Guarantors (as defined therein)
parties thereto and the Trustee, as further supplemented by a ninth supplemental indenture, dated as of September 30, 2006, among the Company the additional Subsidiary Guarantors (as defined therein) party thereto and the Trustee, as further
supplemented by a tenth supplemental indenture, dated as of June 22, 2007, among the Company and the Trustee, as further supplemented by an eleventh supplemental indenture, dated as of June 25, 2007, and to be further supplemented by this Twelfth
Supplemental Indenture (collectively, the “Indenture”), to provide for the issuance by the Company from time to time of Securities to be issued in one or mores series as provided in the Indenture; 

     WHEREAS, the Additional Subsidiary Guarantors intend to guarantee the 6.40% Senior Notes due 2017 and 6.95% Senior Notes due 2037, and, in addition, the Additional AmeriPath Subsidiaries intend to
guarantee the 7.50% Senior Notes due 2011, the 5.125% Senior Notes due 2010 and the 5.45% Senior Notes due 2015 under the Indenture and the issuance of guarantees has been authorized by resolutions adopted by the Boards of Directors of such
Additional Subsidiary Guarantors;

 1 

     WHEREAS, Sections 901(1) and 901(11) of the Indenture provide that without the consent of Holders of the Securities of any series issued under the Indenture, the Company and the Subsidiary Guarantors,
when authorized by a Board Resolution, and the Trustee may enter into one or more indentures supplemental to the Indenture to (a) evidence the successor of another Person to any Subsidiary Guarantor and the assumption by such successor of the
covenants of such Subsidiary Guarantor in the Indenture and in the Securities and (b) add a guarantor or guarantors for any series or all series of the Securities; 

     WHEREAS, pursuant to Sections 904, 1601, 1602 and 1604 of the Indenture, by delivery of a Supplemental Indenture to the Trustee in accordance with the terms of the Indenture, each Person that becomes
a Subsidiary Guarantor after the date of the Base Indenture will be deemed to have executed and delivered the Subsidiary Guarantee for the benefit of the Holder of the Security upon which the Subsidiary Guarantee is endorsed, with the same effect as
if such Subsidiary Guarantor had been named thereon and had executed and delivered the Subsidiary Guarantee; and 

     WHEREAS, all things necessary to make this Twelfth Supplemental Indenture a valid supplement to the Indenture according to its terms and the terms of the Indenture have been done; 

     NOW, THEREFORE, for and in consideration of the foregoing, the parties hereto hereby enter into this Twelfth Supplemental Indenture, for the equal and proportionate benefit of all Holders of the
Securities, as follows: 

     SECTION 1 Certain Terms Defined in the Indenture. 

     All capitalized terms used but not defined herein shall have the meanings assigned to them in the Indenture. 

     SECTION 2 Agreement to Guarantee. 

     The Additional Subsidiary Guarantors, by their signature below, agree to become Additional Subsidiary Guarantors under the Indenture with the same force and effect as if originally named therein as
Subsidiary Guarantors. The Additional Subsidiary Guarantors agree to guarantee the 6.40% Senior Notes due 2017 and 6.95% Senior Notes due 2037, and, in addition, the Additional AmeriPath Subsidiaries intend to guarantee the 7.50% Senior Notes due
2011, the 5.125% Senior Notes due 2010 and the 5.45% Senior Notes due 2015. The Additional Subsidiary Guarantors hereby agree to all the terms and provisions of the Indenture applicable to them as Additional Subsidiary Guarantors thereunder and each
reference to a “Subsidiary Guarantor” in the Indenture shall be deemed to include the Additional Subsidiary Guarantors. 

     SECTION 3 Indenture remains in Full Force and Effect. 

     Except as expressly supplemented by this Twelfth Supplemental Indenture, the Indenture shall remain in full force and effect in accordance with its terms. 

 

2 

     SECTION 4 New York Law to Govern. 

     THIS TWELFTH SUPPLEMENTAL INDENTURE SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO PRINCIPLES OF CONFLICT OF LAWS. 

     SECTION 5 Separability. 

     In case any one or more of the provisions contained in this Twelfth Supplemental Indenture should be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of
the remaining provisions contained herein and in the Indenture shall not in any way be affected or impaired. The parties hereto shall endeavor in good faith negotiations to replace any invalid, illegal or enforceable provisions herein with valid
provisions, the economic effect of which comes as close as possible to that of the invalid, illegal or unenforceable provisions. 

     SECTION 6 May be Executed in Counterparts. 

     This Twelfth Supplemental Indenture may be executed in counterparts, each of which when taken together shall constitute one and the same instrument. This Twelfth Supplemental Indenture shall become
effective when the Trustee shall have received a counterpart thereof that bears the signatures of the Additional Subsidiary Guarantors. 

     SECTION 7 Trustee. 

     The Trustee makes no representations as to the validity or sufficiency of this Twelfth Supplemental Indenture. The recitals and statements herein are deemed to be those of the Company and the
Additional Subsidiary Guarantors and not of the Trustee.

 

3 

     IN WITNESS WHEREOF, the Company, the Additional Subsidiary Guarantors, and the Trustee have duly executed this Twelfth Supplemental Indenture as of the day and year first above written. 

	 	
QUEST DIAGNOSTICS INCORPORATED
	
	 	 

	
	 	
By: s/ Robert A. Hagemann
	
	 	 

	
	 	
Name: Robert Hagemann
	
	 	
Title: Senior Vice President and Chief
	
	 	
          Financial Officer
	
	 	 

	
	 	 

	
	 	
AMERIPATH GROUP HOLDINGS, INC.
	
	 	
AMERIPATH HOLDINGS, INC.
	
	 	
AMERIPATH INTERMEDIATE
	
	 	
    HOLDINGS, INC.
	
	 	
MEDPLUS, INC.
	
	 	 

	
	 	 

	
	 	
By: s/ Robert A. Hagemann
	
	 	 

	
	 	
    Name: Robert Hagemann
	
	 	
    Title: Vice President
	

4 

	 	
THE BANK OF NEW YORK
	
	 	 
	 	
By: s/ Robert A. Massimillo
	
	 	 
	 	
Name: Robert A. Massimillo
	
	 	
Title: Vice President
	

 

 

 

5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00125-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00125-of-00352.parquet"}]]